What is the role of idecabtagene vicleucel (Abecma) in the treatment of multiple myeloma (MM)?

Updated: May 11, 2021
  • Author: Dhaval Shah, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

Idecabtagene vicleucel (Abecma) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous CAR T-cell therapy. In March 2021, the therapy was approved for relapsed or refractory MM after ≥4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. [9]

Approval was based on the KarMMA study, a multicenter, open-label study of idecabtagene vicleucel in patients with relapsed or refractory MM who had received at least 3 prior lines of therapy. At a median follow-up of 13.3 months, 94 of the 128 patients (73%) had a response; 42 of the 128 (33%) had a complete response or better, and 79% of those had minimal residual disease (MRD)–negative status. The median progression-free survival was 8.8 months. Common adverse effects included neutropenia, anemia, thrombocytopenia, and cytokine release syndrome. [118]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!